Evaluating Bempedoic Acid for Non-alcoholic Fatty Liver Disease: A Review of Preclinical and Clinical Research.

Autor:	Anasdeen S M; Department of Pharmacy Practice, College of Pharmacy, SRM Institute of Science and Technology, Chennai, IND., S S; Department of Pharmacy Practice, College of Pharmacy, SRM Institute of Science and Technology, Chennai, IND., Tm V; Department of Pharmacy Practice, College of Pharmacy, SRM Institute of Science and Technology, Chennai, IND.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Aug 18; Vol. 16 (8), pp. e67151. Date of Electronic Publication: 2024 Aug 18 (Print Publication: 2024).
DOI:	10.7759/cureus.67151
Abstrakt:	Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disorder globally, characterized by fat accumulation in liver cells, which can progress to inflammation, fibrosis, and cirrhosis. The disease predominantly affects individuals with obesity and high body mass index (BMI). It is a globally prevalent condition, with variations in incidence across different regions. The pathophysiology of NAFLD involves insulin resistance, metabolic disturbances, and genetic and gut microbial factors. Current treatments primarily focus on lifestyle modifications and a limited range of pharmacological options. Bempedoic acid (BA), a novel cholesterol-lowering agent, targets adenosine triphosphate (ATP)-citrate lyase to reduce low-density lipoprotein (LDL) cholesterol and has shown potential in managing NAFLD by decreasing liver fat accumulation and improving lipid profiles. BA's unique mechanism offers a promising add-on therapy, particularly for the patient's intolerant to statins. Despite its potential, comprehensive clinical and preclinical studies are needed to further elucidate its efficacy and safety compared to other NAFLD treatments. Future research should focus on comparing BA with existing and emerging therapies to optimize its role in NAFLD management and enhance patient outcomes. Competing Interests: Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Anasdeen S et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu